These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 2968875)
1. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Sjövall J; Karlsson A; Ogenstad S; Sandström E; Saarimäki M Clin Pharmacol Ther; 1988 Jul; 44(1):65-73. PubMed ID: 2968875 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection. Sjövall J; Bergdahl S; Movin G; Ogenstad S; Saarimäki M Antimicrob Agents Chemother; 1989 Jul; 33(7):1023-31. PubMed ID: 2528939 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Aweeka F; Gambertoglio J; Mills J; Jacobson MA Antimicrob Agents Chemother; 1989 May; 33(5):742-5. PubMed ID: 2546491 [TBL] [Abstract][Full Text] [Related]
4. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. Jacobson MA; Crowe S; Levy J; Aweeka F; Gambertoglio J; McManus N; Mills J J Infect Dis; 1988 Oct; 158(4):862-5. PubMed ID: 2844921 [No Abstract] [Full Text] [Related]
5. Pharmacokinetics of potential anti-AIDS agents thiofoscarnet and foscarnet in the cat. Straw JA; Loo TL; de Vera CC; Nelson PD; Tompkins WA; Bai SA J Acquir Immune Defic Syndr (1988); 1992; 5(9):936-42. PubMed ID: 1387417 [TBL] [Abstract][Full Text] [Related]
6. The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. Gaub J; Pedersen C; Poulsen AG; Mathiesen LR; Ulrich K; Lindhardt BO; Faber V; Gerstoft J; Hofmann B; Lernestedt JO AIDS; 1987 May; 1(1):27-33. PubMed ID: 2962590 [TBL] [Abstract][Full Text] [Related]
7. Foscarnet. Med Lett Drugs Ther; 1992 Jan; 34(861):3-4. PubMed ID: 1309469 [No Abstract] [Full Text] [Related]
8. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. Reusser P; Gambertoglio JG; Lilleby K; Meyers JD J Infect Dis; 1992 Sep; 166(3):473-9. PubMed ID: 1323614 [TBL] [Abstract][Full Text] [Related]
9. Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring. MacGregor RR; Graziani AL; Weiss R; Grunwald JE; Gambertoglio JG J Infect Dis; 1991 Oct; 164(4):785-7. PubMed ID: 1654363 [TBL] [Abstract][Full Text] [Related]
10. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Chrisp P; Clissold SP Drugs; 1991 Jan; 41(1):104-29. PubMed ID: 1706982 [TBL] [Abstract][Full Text] [Related]
11. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. Jacobson MA; Gambertoglio JG; Aweeka FT; Causey DM; Portale AA J Clin Endocrinol Metab; 1991 May; 72(5):1130-5. PubMed ID: 1827127 [TBL] [Abstract][Full Text] [Related]